AYURDA: Ayurvedic Nutritional Counseling for Patients With IBS in Comparison to Conventional Nutritional Counseling

Sponsor
Charite University, Berlin, Germany (Other)
Overall Status
Completed
CT.gov ID
NCT03019861
Collaborator
(none)
69
2
2
25
34.5
1.4

Study Details

Study Description

Brief Summary

The main goal of this randomized controlled clinical study is to evaluate the efficacy of an individual Ayurvedic nutritional counseling (according to tradition) compared to an individual conventional dietary advice (according to the German Nutrition Society - DGE) in patients with irritable bowel syndrome. It is to be investigated whether nutritional therapy elements, which patients can self-implement independently in the home environment, can achieve sustainable therapy effects.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Ayurvedic nutritional counseling
  • Behavioral: Conventional nutritional counseling
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
69 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Randomized Controlled Study on Ayurvedic Nutritional Counseling for Patients With Irritable Bowel Syndrome in Comparison to Conventional Nutritional Counseling
Actual Study Start Date :
Jan 1, 2017
Actual Primary Completion Date :
Oct 1, 2018
Actual Study Completion Date :
Feb 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Ayurvedic nutritional counseling

Patients will receive three Ayurvedic nutritional counselings (according to tradition) after 1, 3 and 8 weeks after Baseline.

Behavioral: Ayurvedic nutritional counseling

Active Comparator: Conventional nutritional counseling

Patients will receive three conventional nutritional counselings (according to German Nutrition Society - DGE) after 1, 3 and 8 weeks after Baseline.

Behavioral: Conventional nutritional counseling

Outcome Measures

Primary Outcome Measures

  1. Irritable Bowel Syndrome-Severity Scoring System (IBS-SSS) - Change [Change from IBS-SSS Baseline at 12 weeks]

Secondary Outcome Measures

  1. Cohen Perceived Stress Scale (CPSS) - Change [Change from CPSS Baseline at 4 weeks, 12 weeks and 6 months]

  2. Hospital Anxiety and Depression Scale (HADS-D) - Change [Change from HADS-D Baseline at 4 weeks, 12 weeks and 6 months]

  3. Irritable bowel Syndrome - Quality of life (IBS-QOL) - Change [Change from IBS-QOL Baseline at 4 weeks, 12 weeks and 6 months]

  4. VAS: Pain, Sleep, General bothersomeness, Expectation - Change [Change from VAS Baseline at 4 weeks, 12 weeks and 6 months]

  5. Irritable Bowel Syndrome-Severity Scoring System (IBS-SSS) - Change [Change from IBS-SSS Baseline at 4 weeks and 6 months]

Other Outcome Measures

  1. Stool analysis: Intestinal microbiome by sequencing 16S rRNA [Baseline, 4 weeks]

  2. Qualitative interviews in focus groups [Baseline, 6 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis "irritable bowel syndrome" according to the ROM-III criteria and the German S3 guideline (Layer 2011)

  • Female and male patients between 18 and 70 years of age

  • Declaration of consent

Exclusion Criteria:
  • Bad general condition

  • Serious acute or chronic comorbidity

  • Pregnancy and breast feeding period

  • Eating disorder

  • In recognition procedures for early retirement or disability

  • Simultaneous participation in another clinical trial

  • Participation in a clinical trial within the last 3 months before enrollment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kliniken Essen-Mitte Essen Am Deimelsberg 34 A Germany 45276
2 Charité Hochschulambulanz für Naturheilkunde am Immanuel Krankenhaus Berlin Germany 14109

Sponsors and Collaborators

  • Charite University, Berlin, Germany

Investigators

  • Principal Investigator: Andreas Michalsen, Prof. Dr., Charité University Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Andreas Michalsen, Principal Investigator, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier:
NCT03019861
Other Study ID Numbers:
  • AYURDA
First Posted:
Jan 13, 2017
Last Update Posted:
Aug 6, 2021
Last Verified:
Aug 1, 2021
Keywords provided by Andreas Michalsen, Principal Investigator, Charite University, Berlin, Germany
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 6, 2021